F-star Therapeutics Overview
F-star Therapeutics (FSTX) has a P/E ratio of -3.79, below the Healthcare sector average of 27.42.
Get informed when a big investor buys or sells
+ Follow-3.79
The P/E ratio compares a company's stock price to its earnings per share. A lower P/E ratio may indicate that the stock is undervalued.
F-star Therapeutics (FSTX) currently reports a P/E ratio of -3.79. That is below the Healthcare sector average of 27.42. Use the charts on this page to explore F-star Therapeutics's P/E ratio history and peer comparisons.
F-star Therapeutics's P/E ratio of -3.79 is lower than the Healthcare sector average of 27.42. That is roughly 113.8% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
The P/E ratio is a valuation multiple that relates F-star Therapeutics's market price to a fundamental measure such as earnings, sales, or book value. At -3.79, FSTX can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.
Start with the current P/E ratio of -3.79, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 27.42. From there, open related valuation or income-statement pages for F-star Therapeutics, and consider following FSTX for alerts when major investors trade the stock.
F-star Therapeutics is classified in the Healthcare sector. On P/E ratio, it currently shows -3.79 versus a sector average near 27.42. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing FSTX with unrelated industries.
